Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OurofinoBSP:OFSA3 -2.69%68 3-1 Month Momentum % is -5.10% as of Jul. 19, 2026. GuruFocus rates BSP:OFSA3 with a GF Score™ of 68/100 and a GF Value™ of R$26.79 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,020 Drug Manufacturers companies, Ourofino ranks better than 59.41% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-19), Ourofino's 3-1 Month Momentum % is -5.10%.
The industry rank for Ourofino's 3-1 Month Momentum % or its related term are showing as below:
BSP:OFSA3's 3-1 Month Momentum % is ranked better than 59.41% of 1020
companies
in the Drug Manufacturers industry
Industry Median: -9.975
vs BSP:OFSA3: -5.10
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Ourofino 3-1 Month Momentum % Related Terms
BSP:OFSA3 vs ZTS, UTHR, VTRS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ourofino's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ourofino 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ourofino's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Ourofino's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ourofino (BSP:OFSA3) has a 3-1 Month Momentum % of -5.10% as of Jul. 19, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Ourofino and its competitors. According to the industry distribution chart, Ourofino ranks #414 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 40.6%.
Is Ourofino's 3-1 Month Momentum % too high?
Ourofino's current 3-1 Month Momentum % is -5.10%. Based on the distribution chart, Ourofino ranks #414 out of 1020 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ourofino has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ourofino's 3-1 Month Momentum % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ourofino ranks #414 out of 1020 companies for 3-1 Month Momentum %. This puts Ourofino in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Ourofino and its competitors. Ourofino's current 3-1 Month Momentum % is -5.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ourofino stock overvalued right now?
Based on GuruFocus' analysis, Ourofino (BSP:OFSA3) is currently considered Fairly Valued. The stock's GF Value™ is R$26.79, compared to a current price of R$25.30 — trading 5.6% below its estimated fair value. The current 3-1 Month Momentum % is -5.10%. Ourofino's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Ourofino (BSP:OFSA3), the current 3-1 Month Momentum % is -5.10% as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ourofino (BSP:OFSA3) Overvalued in 2026?
Based on GuruFocus' analysis, Ourofino stock appears to be undervalued.
The current stock price of R$25.30 is trading 5.6% below its estimated GF Value™ of R$26.79.
GuruFocus considers Ourofino to be Fairly Valued.
Key valuation signals for BSP:OFSA3:
3-1 Month Momentum %: -5.10%
GF Value™: R$26.79 vs. price of R$25.30 (5.6% below fair value)
No single metric tells the full story. See the BSP:OFSA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.
68GF Score
Get the complete analysis for BSP:OFSA3
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:OFSA3 has been successfully added to your 
